AP
IONS icon

AHL Partners’s Ionis Pharmaceuticals IONS Stock Holding History

AHL Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,092
Closed -$1.02M – 1299
2017
Q3 		$1.02M Buy
+20,092
New +$1.05M 0.02% 877
2016
Q4 		– Sell
-8,036
Closed -$294K – 1108
2016
Q3 		$294K Buy
+8,036
New +$251K 0.01% 983
2016
Q1 		– Sell
-26,107
Closed -$1.62M – 791
2015
Q4 		$1.62M Buy
+26,107
New +$1.41M 0.13% 300
2015
Q3 		– Sell
-60,356
Closed -$3.47M – 746
2015
Q2 		$3.47M Buy
60,356
+38,753
+179% +$2.46M 0.14% 338
2015
Q1 		$1.38M Buy
21,603
+15,866
+277% +$1.08M 0.05% 539
2014
Q4 		$354K Buy
+5,737
New +$283K 0.02% 677

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

AHL Partners's IONS Position: Q4 2017 in Review

AHL Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2017, closing a stake of 20,092 shares — an estimated $1.02M sold.

AHL Partners first reported a position in IONS in Q4 2014 and held it in 6 quarters. The position peaked at $3.47M in Q2 2015. 316 funds tracked by Wall St. Rank hold IONS as of Q4 2017.

  • AHL Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • AHL Partners sold 20,092 Ionis Pharmaceuticals shares in Q4 2017, an estimated $1.02M.
  • AHL Partners first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • AHL Partners's Ionis Pharmaceuticals position peaked at $3.47M in Q2 2015.
  • 316 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.